See more : eDreams ODIGEO S.A. (0QS9.L) Income Statement Analysis – Financial Results
Complete financial analysis of Seer, Inc. (SEER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seer, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Samsung Fire & Marine Insurance Co., Ltd. (000810.KS) Income Statement Analysis – Financial Results
- Enwell Energy plc (RGPMF) Income Statement Analysis – Financial Results
- Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) Income Statement Analysis – Financial Results
- Knowles Corporation (KN) Income Statement Analysis – Financial Results
- Klondike Gold Corp. (KDKGF) Income Statement Analysis – Financial Results
Seer, Inc. (SEER)
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.18M | 14.69M | 6.39M | 656.00K | 58.00K | 0.00 |
| Cost of Revenue | 8.16M | 7.94M | 3.21M | 0.00 | 701.00K | 100.00K |
| Gross Profit | 7.03M | 6.74M | 3.19M | 656.00K | -643.00K | -100.00K |
| Gross Profit Ratio | 46.29% | 45.91% | 49.87% | 100.00% | -1,108.62% | 0.00% |
| Research & Development | 53.02M | 45.80M | 29.12M | 18.94M | 12.39M | 3.78M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 15.36M | 4.61M | 2.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 58.95M | 58.53M | 45.76M | 15.36M | 4.61M | 2.98M |
| Other Expenses | 0.00 | -351.00K | -223.00K | -9.00K | -58.00K | 0.00 |
| Operating Expenses | 111.97M | 103.98M | 74.66M | 34.31M | 16.94M | 6.76M |
| Cost & Expenses | 120.12M | 111.92M | 77.87M | 34.31M | 16.94M | 6.76M |
| Interest Income | 17.76M | 4.60M | 326.00K | 883.00K | 850.00K | 451.00K |
| Interest Expense | 0.00 | 327.00K | 22.00K | 9.00K | 5.00K | 0.00 |
| Depreciation & Amortization | 5.58M | 5.90M | 3.56M | 1.61M | 701.00K | 100.00K |
| EBITDA | -97.89M | -93.29M | -68.59M | -31.17M | -15.33M | -6.21M |
| EBITDA Ratio | -644.74% | -633.07% | -1,112.72% | -4,994.82% | -26,434.48% | 0.00% |
| Operating Income | -103.46M | -97.24M | -71.47M | -33.65M | -16.88M | -6.76M |
| Operating Income Ratio | -681.48% | -662.14% | -1,117.81% | -5,129.42% | -29,108.62% | 0.00% |
| Total Other Income/Expenses | 17.19M | 4.27M | 304.00K | 874.00K | 845.00K | 451.00K |
| Income Before Tax | -86.28M | -92.97M | -71.17M | -32.78M | -16.04M | -6.31M |
| Income Before Tax Ratio | -568.28% | -633.07% | -1,113.06% | -4,996.19% | -27,651.72% | 0.00% |
| Income Tax Expense | 0.00 | -4.27M | -2.54M | -1.61M | 5.00K | 451.00K |
| Net Income | -86.28M | -88.70M | -68.63M | -31.17M | -16.04M | -6.31M |
| Net Income Ratio | -568.28% | -604.00% | -1,073.40% | -4,751.37% | -27,660.34% | 0.00% |
| EPS | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| EPS Diluted | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| Weighted Avg Shares Out | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
| Weighted Avg Shares Out (Dil) | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
SEER RECEIVES CONTRACT FROM BIOCHAR NOW FOR THE MANUFACTURING OF KILNS AND INTENDS TO OPEN A JV TEXAS BIOCHAR FACILITY
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study
Lab Instrument Industry Update - New Commercial Entrants
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
Seer Reports First Quarter 2024 Financial Results
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
Source: https://incomestatements.info
Category: Stock Reports